Compare Amylx Pharmaceuticals Inc (AMLX) vs Cincinnati Financial Corporation (CINF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Cincinnati Financial Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Cincinnati Financial Corporation trades at $180.5 (market cap $27.73B). The key difference: Cincinnati Financial Corporation is far larger — about 14× Amylx Pharmaceuticals Inc's market cap, and Cincinnati Financial Corporation pays a 2.1% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | CINF | |
|---|---|---|
Market Cap | $1.98B | $27.73B |
Sector | Health | Financials |
52-Week High | $18.70 | $192.03 |
52-Week Low | $7.64 | $145.80 |
Enterprise Value | $1.70B | $27.41B |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
CINF trades at $179.28, up 2.19% today, near its consensus price target of $185.75. The stock shows strong fundamentals with a P/E of 10.25, net income margin of 21.33%, and consistent earnings beats in recent quarters. Technical indicators are bearish overall, with the current price near the pivot point of $178. Recent news highlights a scheduled Q2 2026 earnings webcast and a 65-year dividend streak, with a $0.94 dividend paid in July 2026.
Outlook remains positive due to valuation appeal and earnings momentum, but risks include technical bearish signals and exposure to catastrophe losses. Revenue growth is steady, projected to reach $12.9B in 2026, supporting a bullish analyst consensus despite mixed technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →
